A randomized controlled clinical trial of intranasal versus subcutaneous midazolam for agitation in terminal illness (MinTU study)

Key Points

• To evaluate the effectiveness of intranasal versus subcutaneous midazolam in managing agitation among patients with terminal illness.
• Randomized controlled trial design
• Comparison between intranasal and subcutaneous midazolam
• Participants experiencing agitation due to terminal illness
• Effectiveness of intranasal midazolam demonstrated in managing agitation
• Subcutaneous midazolam showed similar effectiveness
• No significant differences found between the two administration routes